Skip to content

Study · Animal study (in vivo) · rat · 2004

4 results

The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats.

Banno R, Arima H, Sato I, Hayashi M, Goto M, Sugimura Y, Murase T, Oiso Y

Peptides1 Aug 2004Cited by 10 (Europe PMC)

PMID15350695 (opens in a new tab)DOI10.1016/j.peptides.2004.05.007 (opens in a new tab)PepBankPUB-15350695
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In OLETF rats, subcutaneous MTII infusion decreased food intake.

    In plain wordsIn OLETF rats, MTII infusion under the skin reduced food intake.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake
    Study

    ratn: not reported in source

    OLETF rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (osmotic mini-pumps)As given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of MTII with osmotic mini-pumps decreased food intake and body weight in OLETF rats.
    1 context sentence
    Summary · context
    Effects of peripheral administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity and glucose tolerance were examined in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In OLETF rats, subcutaneous MTII infusion decreased body weight.

    In plain wordsIn OLETF rats, MTII infusion under the skin reduced body weight.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight
    Study

    ratn: not reported in source

    OLETF rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (osmotic mini-pumps)As given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of MTII with osmotic mini-pumps decreased food intake and body weight in OLETF rats.
    1 context sentence
    Summary · context
    Effects of peripheral administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity and glucose tolerance were examined in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In OLETF rats, MTII increased insulin sensitivity in insulin tolerance tests on day 9 compared with ad libitum-fed and pair-fed rats.

    In plain wordsIn OLETF rats, MTII improved insulin sensitivity more than free feeding or matched food restriction did.

    Peptide
    Melanotan II
    Outcome
    IncreaseInsulin sensitivity in insulin tolerance test (day 9)
    Study

    ratn: not reported in source

    OLETF rats
    Comparator
    Ad libitum-fed and pair-fed rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (osmotic mini-pumps)As given in this study (rat).

    Source sentences

    Summary
    MTII group showed more sensitivity to insulin compared with that allowed to eat ad libitum or pair-fed group in insulin tolerance tests on day 9.
    1 context sentence
    Summary · context
    Effects of peripheral administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity and glucose tolerance were examined in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In OLETF rats, MTII gave significantly lower glucose values than ad libitum feeding in glucose tolerance tests on days 11 and 23.

    In plain wordsIn OLETF rats, MTII gave lower blood glucose in glucose tolerance tests than free feeding did.

    Peptide
    Melanotan II
    Outcome
    DecreaseGlucose values in glucose tolerance test (days 11 and 23)
    Study

    ratn: not reported in source

    OLETF rats
    Comparator
    Ad libitum-fed rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (osmotic mini-pumps)As given in this study (rat).

    Source sentences

    Summary
    MTII group also showed significantly lower glucose values than ad libitum group in glucose tolerance tests on days 11 and 23.
    1 context sentence
    Summary · context
    Effects of peripheral administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity and glucose tolerance were examined in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.